# Combination Therapy With 5-Fluorouracil, Interferon-an Interleukin-2, & Thalidomide for Metastatic, Advanced or Recurrent Renal Cell Carcinoma

> **NCT00277017** · PHASE1,PHASE2 · COMPLETED · sponsor: **New Mexico Cancer Research Alliance** · enrollment: 15 (actual)

## Conditions studied

- Kidney
- Cancer

## Interventions

- **DRUG:** 5-Flourouracil, Interferon-a, IL-2 and Thalidomide

## Key facts

- **NCT ID:** NCT00277017
- **Lead sponsor:** New Mexico Cancer Research Alliance
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-09
- **Primary completion:** 2005-08
- **Final completion:** 2005-08
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2011-09-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00277017

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00277017, "Combination Therapy With 5-Fluorouracil, Interferon-an Interleukin-2, & Thalidomide for Metastatic, Advanced or Recurrent Renal Cell Carcinoma". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT00277017. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*